ITW

MAR 0 9 2007

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction avt of 1995, n	U.S. Patent o persons are required to respond to a collection	and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number.								
TRADE MARKET	Application Number	10/815,449 4/1/04 Yvo Graus								
TRANSMITTAL	Filing Date									
FORM	First Named Inventor									
(to be used for all correspondence after initial fili	ing) Art Unit	1614								
	Examiner Name									
Total Number of Pages in This Submission	Attorney Docket Number	21655 US2								
ENCLOSURES (Check all that apply)										
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks cited art	After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):								
Response to Missing Parts under 37 CFR 1.52 or 1.53	URE OF APPLICANT, ATTORNE	EV OR ACENT								
Firm	UNL OF AFFLICANT, ATTORNE	.I, OR AGENT								
or Individual name David E. Wildma										
Date Mar. 7, 2007										
	RTIFICATE OF TRANSMISSION									
		deposited with the United States Postal Service with ents, P.O. Box 1450, Alexandria, VA 22313-1450 on								
Typed or printed name David E.W	fildman // / (
Signature	SVU	Date Mar. 7, 2007								

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT APPLICATION



In re Patent Application

Inventor(s) Graus et al

Group: 1614

Application No. 10/815,449, filed Apr. 1, 2004

Examiner:

(Case Docket No. 21655 US2)

For: ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR

AND USES THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 March 7, 2007

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A2, and B4-B5 listed on Form PTO-1449 are enclosed.

Enclosed is a Search Report, dated December 22, 2006, which was issued by the Austrian Patent Office in the 200506244-3 application corresponding to the captioned application. The Search Report lists Documents A2, and B4-B5.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted after the first Office Action on the merits and after three months of the filing date for the captioned application, there is enclosed a Certificate under 37 C.F.R. § 1.97(e).

Respectfully submitted,

Attorney for Applicant(s)

David E. Wildman (Reg. No. 40226) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6385 Telefax: (973) 235-2363

285531





In re Patent Application

Graus et al

Group: 1614

Application No. 10/815,449, filed Apr. 1, 2004

Examiner:

(Case Docket No. 21655 US2)

For:

ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND USES THEREOF

STATEMENT UNDER 37 CFR § 1.97(e)

Nutley, New Jersey 07110 March 7, 2007

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify:

X That each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement.

That <u>no</u> item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Attorney of Record David E. Wildman (Reg. No. 40226)

Telephone: (973) 235-6385 Telefax: (973) 235-2363

Substitute for form 1449A/PTO INFORMATION DISCLOSURE								Complete if Known						
								Application Number 10/815,			315,4	49		
STATEMENT BY APPLICANTE								Filing Date		4/1/	4/1/04			
								First Name Inventor		Yvo	Gra	us		
		(Use sev	eral shee	ts if	iecessa	ry)	9 2007 B	10	Group Art Unit	1614				
					l _	AR U	<u> </u>	Examiner Name						
Sheet	1		of	1	13/		Æ)	Attorney Docket Number 21655				US2		
LIST ATENT DOCUMENTS														
			U.S. Patent Document											
Examiner Initials'		Cite No. ¹	Kind Code ²			ind Code ²		Name of Patentee or Appl	icant o	of	Date of Publication of			
					(if known)	Cited Document				Cited document MM-DD-YYYY				
	_	4.2	2004	2004/0018191		Wang et al			01-29-2004					
	A2		2004/0018191				-	Wang et al			01-29-2004			
	_							\dashv						
<u></u>								_				·		
										_				
-									II. 8 1.1					
,					-			\dashv						
	-							\dashv	· · · · · · · · · · · · · · · · · · ·			-		
	\dashv							_					_	
	_													
	_							_						
								'A'	TENT DOCUMENTS					
		Cite No.1	Foreign Patent Document				ent		ar con .	Date of Publication of To				
Examine Initials'	er		Office ³ Numbe		er•	r Kind Coo		Name of Patentee or Applicant of Cited Docum			ited Document IM-DD-YYYY			
minais	\dashv		1110		(1000		(if known)					<u> </u>		
	_	B4	WO 03/100008						Schering Corp			-04-2003		
		B5	WO 03/059951			Pierre Fabre	07-		24-2003					
	_					Medicament								
	[]						_						
												· ·]	
							-			o				
										\dashv	-			
		-	-				-			$\overline{}$			 	
	-									\dashv			<u> </u>	
· · · · · · · · · · · · · · · · · · ·										\dashv			├	
	_													
													<u> </u>	
Examine Signatur			Date C	Cons	sidered	[

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

This is the communication to applicant.

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.